Pulse Health's Revelar device helps minimize free radical damage

Pulse Health announces Revelar™ the first non-invasive device to help healthcare professionals and their patients measure aldehydes and help minimize free radical damage. Revelar is breakthrough breath technology that accurately detects and measures the presence of aldehydes, which are indicators of free radical damage in the body (research, Rapid Commun Mass Spectrum 2003).

Free radicals are molecules, present in every person, but can become unstable leading to cell damage and eventually disease. Free radical damage is also referred to as oxidative stress or simply cell or tissue damage. Extensive scientific research has shown that an overabundance of free radicals is associated with many degenerative diseases including heart and lung disease, cancer, and premature aging (research, American Journal of Epidemiology 2001). Factors that may contribute to production of free radicals include diet, activity level, stress, chemicals, pollutants and other factors.

"Oxidative stress may be one of the most important and least understood phenomena in the human body. It affects all major systems, and plays a key role in accelerating heart disease and cancer risk," observed Dr. Dan Murphy, a leading instructor of chiropractic medicine to the profession. "A measurement tool such as Revelar provides a new way to give patients a very specific method to measure aldehydes, help reduce free radical damage and ultimately improve health."

To limit the effects of free radical damage, millions of Americans take antioxidant supplements, fueling a multi-billion dollar industry. The right antioxidants, as well as a regimen of exercise, diet, and stress reduction, can help the body effectively process free radicals and reduce damage to healthy cells. However, because there are many antioxidant supplements available, some effective and some not, and also because everyone's body reacts differently to particular antioxidants, it is important to use products that reduce free radical damage for that individual. Until now, there was no accurate way to measure whether antioxidants and other treatment plans were working to lower aldehyde levels.

"Revelar's measurement system is the gold standard for measuring free radical damage," John Hunt M.D., Pediatric Respiratory Medicine, University of Virginia. "There is a lot of subjective information in the market, but now a doctor can accurately determine whether a regime is working and enable patients to improve their health and understand why it's improving."

With Revelar you can measure the level of aldehydes versus forms of intervention such as antioxidant supplements and exercise. The first Revelar test score provides a baseline. Continued testing will help healthcare providers to consider how effective antioxidant supplements, lifestyle changes and other forms of treatment may be. The ultimate goal is to help people improve their health over time.

"Keeping the athlete's body in the best condition possible is paramount to their continued success on the court or the field," says Coach Dave Shelofsky, a seasoned strength and conditioning coach who has integrated the Revelar device into his training programs. "We all know that free radical damage can be reversed with improved diets, the right supplements, and a strong training regiment. I finally have a way to show my athletes what sort of damage they are doing to themselves internally with their poor choices. Now we work together as a team to improve their individual Revelar scores, thereby enhancing performance and promoting faster recoveries." Coach Dave's programs focus on off-season development and injury rehabilitation for professional athletes from the NBA, NFL, MLB and NHL, as well as from college sports.

Pulse Health has signed three large distribution deals worth several million dollars that will make Revelar available to the healthcare and fitness markets. Revelar is available to health related Practitioners at www.revelar.com.

In 2010, Pulse Health was awarded a $488,959 grant under IRS Section 48D for Qualifying Therapeutic Discovery Projects in order to develop and bring to market the Revelar breath technology.